Teva and Ivax Bet on French Generics

Although generics still account for a paltry percentage of prescription drug usage in France, Ivax and Teva reckon the market is set to grow. Last April Ivax acquired all the products within Merck Sharpe & Dohme; just days later, Teva bought Bayer's French generics business. Teva and Ivax clearly hope that France-the world's fourth largest drug market-will follow its neighbors Germany and the UK, where generics represent a far greater proportion of the total pharmaceutical market.

Although generics still account for a paltry percentage of prescription drug usage in France, Ivax Corp. and Teva Pharmaceutical Industries Ltd. reckon the market is set to grow. Last April Ivax acquired all the products within Merck & Co. Inc. 's French subsidiary Laboratoire Merck Sharpe & Dohme (MSD)-Chibret, and just days later, Teva bought Bayer Classics SA , Bayer AG 's French generics business, ranked third in France in 2001 [See Deal][See Deal].

Teva and Ivax hope France—the world's fourth largest drug market—will follow its neighbors Germany and the UK, where generics represent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By 

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.